2. GPCR/G Protein Immunology/Inflammation
  3. CXCR
  4. NVP CXCR2 20

NVP CXCR2 20 is a selective CXCR2 inhibitor with analgesic and antinociceptive activities. NVP CXCR2 20 selectively blocks CXCR2 signaling and attenuates mechanical and thermal hypersensitivity in rat chronic constriction injury (CCI) models. NVP CXCR2 20 inhibits CXCL3-induced hypersensitivity in naive mice and reduces elevated CXCL3 protein levels in the spinal cord and dorsal root ganglia (DRG) of CCI-exposed rats. NVP CXCR2 20 can be used for the research of neuropathic pain and chronic obstructive pulmonary disease (COPD).

For research use only. We do not sell to patients.

NVP CXCR2 20

NVP CXCR2 20 Chemical Structure

CAS No. : 1029521-30-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

NVP CXCR2 20 Related Antibodies

Top Publications Citing Use of Products

View All CXCR Isoform Specific Products:

View All Isoforms
CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NVP CXCR2 20 is a selective CXCR2 inhibitor with analgesic and antinociceptive activities. NVP CXCR2 20 selectively blocks CXCR2 signaling and attenuates mechanical and thermal hypersensitivity in rat chronic constriction injury (CCI) models. NVP CXCR2 20 inhibits CXCL3-induced hypersensitivity in naive mice and reduces elevated CXCL3 protein levels in the spinal cord and dorsal root ganglia (DRG) of CCI-exposed rats. NVP CXCR2 20 can be used for the research of neuropathic pain and chronic obstructive pulmonary disease (COPD)[1][2][3].

IC50 & Target[1]

CXCR2

4.9 μM (IC50)

In Vitro

NVP CXCR2 20 (100 nM; 30 min pre-incubation, 24 h with LPS) reduces LPS-induced CXCL1, CXCL2, and CXCL3 protein expression in primary rat microglial cell cultures and astroglial cell cultures[1].
NVP CXCR2 20 (0.0005–10 μM) binds to human recombinant CXCR2 in CHO membranes with an IC50 of 0.04 μM and acts as a functional CXCR2 antagonist with an [35S]-GTPγS IC50 of 0.14 μM; it shows a cLogP of 3.9 and a functional ligand-lipophilicity efficiency (LLE) of 3.0[3].
NVP CXCR2 20 (10 μM) is selective for CXCR2, with no significant inhibitory activity (IC50 > 10 μM) against a panel of 49 other GPCRs[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NVP CXCR2 20 Related Antibodies
In Vivo

NVP CXCR2 20 (10-30 μg/5 μL; intrathecal; single dose or 16 h and 1 h post-CCI, then once daily for 7 days) dose-dependently attenuates mechanical and thermal hypersensitivity in CCI-induced neuropathic pain in rats, with repeated 10 μg/5 μL doses reducing hypersensitivity on days 2 and 7 post-CCI and normalizing CXCL3 protein levels in the spinal cord and DRG without affecting glial activation[1].
NVP CXCR2 20 (10 μg/5 μL; intrathecal; single dose on day 7 post-CCI, 4 hours prior to opioid co-administration) produces analgesic effects[1].
NVP CXCR2 20 (60 μg/5 μL; intrathecal; single dose, 2 hours prior to intrathecal CXCL3) prevents CXCL3-induced mechanical and thermal hypersensitivity in naive mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (male, adult, 250-300 g, chronic constriction injury of the sciatic nerve with intrathecal catheter implantation 7 days prior)[1]
Dosage: 10 μg/5 μL (repeated administration); 20 μg/5 μL (single administration); 30 μg/5 μL (single administration)
Administration: intrathecal; single dose (single treatment); 16 h and 1 h post-CCI, then once daily for 7 days (repeated treatment)
Result: Produced significant analgesic effects on mechanical and thermal hypersensitivity at 2, 4, and 6 h after single administration (20 and 30 μg/5 μL).
Reduced mechanical hypersensitivity and thermal hypersensitivity after repeated dosing (10 μg/5 μL).
Normalized elevated CXCL3 protein in spinal cord and DRG to naive levels.
Did not affect CCI-induced spinal IBA1 (microglia) or GFAP (astroglia) upregulation.
Animal Model: Wistar rats (male, adult, 250-300 g, chronic constriction injury of the sciatic nerve with intrathecal catheter implantation 7 days prior)[1]
Dosage: 10 μg/5 μL
Administration: intrathecal; single dose (day 7 post-CCI, 4 hours prior to opioid co-administration)
Result: Produced analgesic effects similar to single doses of morphine or buprenorphine in the von Frey and cold plate tests.
Animal Model: Albino Swiss mice (20-22 g)[1]
Dosage: 60 μg/5 μL
Administration: intrathecal; single dose, 2 hours prior to intrathecal CXCL3
Result: Completely prevented the mechanical and thermal hypersensitivity induced by CXCL3 in naive mice at all tested time points (1.5, 5, and 24 hours post-CXCL3 administration).
Molecular Weight

319.33

Formula

C15H11F2N3OS
CAS No.
SMILES

N#CC=1C(=O)N=C(SCC=2C=CC=C(F)C2F)NC1C3CC3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

NVP CXCR2 20 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NVP CXCR2 201029521-30-9CXCRCXC chemokine receptorsC-X-C motif chemokine receptorsspinal cordCXCR2primary rat astroglial cell culturesnaive micedorsal root gangliaCXCL3chronic obstructive pulmonary diseaseprimary rat microglial cell culturesrat chronic constriction injury modelsneuropathic painInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NVP CXCR2 20
Cat. No.:
HY-110268
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.